Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH)

Details for Australian Patent Application No. 2005253749 (hide)

Owner Novo Nordisk Health Care AG

Inventors Skolnick, Brett E.; Brun, Nikolai Constantin; Erhardtsen, Elisabeth

Agent Shelston IP

Pub. Number AU-A-2005253749

PCT Pub. Number WO2005/123118

Priority PA 2004 00981 23.06.04 DK; PA 2004 00972 21.06.04 DK

Filing date 21 June 2005

Wipo publication date 29 December 2005

International Classifications

A61K 38/48 (2006.01) Medicinal preparations containing peptides

Event Publications

25 January 2007 PCT application entered the National Phase

  PCT publication WO2005/123118 Priority application(s): WO2005/123118

23 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005253754-Method of preventing the induction of aberrations in laser refractive surgery systems

2005253743-Antistatic footwear